Clark R B, Pakiz C B, Hostetter M K
Department of Pathology, Crozer-Chester Medical Center, Upland, Chester, PA 19013.
Med Microbiol Immunol. 1990;179(2):77-86. doi: 10.1007/BF00198528.
The bactericidal activity of aminoglycosides alone and in combination with various beta-lactams was studied by the time-kill technique against ten Pseudomonas aeruginosa isolates with an unusual antibiogram (amikacin-resistant, gentamicin-resistant, tobramycin-susceptible [ArGrTs]). Previous studies have indicated that ArGrTs isolates are moderately resistant to all aminoglycosides and many are multiply resistant to beta-lactams. Aminoglycoside-beta-lactam combinations showed infrequent synergistic (16%) or enhanced killing (12%) against the ArGrTs isolates. Synergistic activity, when present, was more likely to occur with tobramycin and amikacin than with gentamicin, even though these differences were not statistically significant. Antibiotic resistance patterns were not predictive of synergy or enhanced killing. Systemic infections produced by ArGrTs isolates that are multiply resistant to the beta-lactams may not respond to combination therapy with an aminoglycoside and beta-lactam. Alternative treatment with polymyxin B or a quinolone may be required for these infections.
采用时间杀菌技术,研究了氨基糖苷类抗生素单独使用以及与各种β-内酰胺类抗生素联合使用时,对10株具有不寻常抗菌谱(耐阿米卡星、耐庆大霉素、对妥布霉素敏感[ArGrTs])的铜绿假单胞菌分离株的杀菌活性。先前的研究表明,ArGrTs分离株对所有氨基糖苷类抗生素均具有中度耐药性,且许多菌株对β-内酰胺类抗生素多重耐药。氨基糖苷类-β-内酰胺类抗生素联合用药对ArGrTs分离株的协同作用(16%)或增强杀菌作用(12%)并不常见。即使这些差异无统计学意义,但协同活性一旦出现,与妥布霉素和阿米卡星联合时比与庆大霉素联合时更易发生。抗生素耐药模式无法预测协同作用或增强杀菌作用。对β-内酰胺类抗生素多重耐药的ArGrTs分离株引起的全身感染,可能对氨基糖苷类抗生素与β-内酰胺类抗生素的联合治疗无反应。这些感染可能需要用多粘菌素B或喹诺酮类药物进行替代治疗。